Department Of Neurology 10
451. Diagnosis and classification of optic neuritis
452. Diagnosis and classification of optic neuritis
453. Diagnosis and classification of optic neuritis
454. Diagnosis and classification of optic neuritis
455. Diagnosis and classification of optic neuritis
456. Diagnosis and classification of optic neuritis
457. Diagnosis and classification of optic neuritis
458. Diagnosis and classification of optic neuritis
459. Diagnosis and classification of optic neuritis
460. Diagnosis and classification of optic neuritis
461. Diagnosis and classification of optic neuritis
462. Diagnosis and classification of optic neuritis
463. Diagnosis and classification of optic neuritis
464. Diagnosis and classification of optic neuritis
465. Diagnosis and classification of optic neuritis
466. Diagnosis and classification of optic neuritis
467. Diagnosis and classification of optic neuritis
468. Diagnosis and classification of optic neuritis
469. Diagnosis and classification of optic neuritis
470. Diagnosis and classification of optic neuritis
471. Diagnosis and classification of optic neuritis
472. Diagnosis and classification of optic neuritis
473. Diagnosis and classification of optic neuritis
474. Diagnosis and classification of optic neuritis
475. Diagnosis and classification of optic neuritis
476. Modern Approaches to Diagnosing Cognitive Impairments in Patients with Multiple Sclerosis
477. Predictors of Anxiety and Depression in Patients with Chronic Viral Hepatitis in Kazakhstan
478. Neurocritical Care Organization in the Low-Income and Middle-Income Countries
479. Neurocritical Care Organization in the Low-Income and Middle-Income Countries
480. Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates
481. Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates
482. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
483. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
484. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
485. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
486. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage The Global Burden of Disease Study 2021
487. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
488. Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss
489. Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss
490. Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss
491. Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss
492. Establishing prognostic significance of hypoxia predictors in patients with acute cerebral pathology
493. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
494. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
495. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
496. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
497. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
498. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
499. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
500. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
1 8 9 10 11 12 13